AIVF
 | |
| Company type | Private |
|---|---|
| Industry | Biotechnology, Fertility |
| Founded | 2018 |
| Founder | Daniella Gilboa, Daniel Seidman |
| Headquarters | Tel Aviv , Israel |
Key people | Daniella Gilboa (CEO), Daniel Seidman (Chief Medical Officer) |
| Products | EMA by AIVF software platform |
| Services | AI driven IVF operating system |
| Website | https://www.aivf.com |
AIVF is Tel Aviv-based healthtech startup focused on revolutionizing in-vitro fertilization (IVF) through the application of artificial intelligence (AI). The main company's product is EMA software platform.
History
[edit]AIVF was founded in 2018 in Tel Aviv, Israel, by Daniella Gilboa, a clinical embryologist, and Prof. Daniel Seidman, a reproductive endocrinologist and IVF expert. AIVF aims to improve the success rates of IVF treatments and shorten the time to pregnancy.[1]
In 2019, the company secured financial support from angel investors, venture capital firms, and grants from the Israel Innovation Authority and the European R&D program Eureka.[2][3]
In 2021, AIVF's EMA software received the CE Mark, indicating compliance with European health, safety, and environmental protection standards. The company is also GDPR and HIPAA-compliant, ensuring the privacy and security of patient data.[4][5][6]
In June 2022, AIVF raised $25 million in Series A financing led by Insight Partners, with participation from Adam Neumann's Family Office.[7][8]
Technology
[edit]AIVF's product is the EMA platform, an AI-powered system that evaluates the viability of embryos during IVF procedures. EMA analyzes biological data from embryos from Day Zero (fertilization) to Day 5 or Day 6, scoring them based on their probability of successful implantation and pregnancy.[9] This technology aims to standardize the embryo evaluation process across clinics, reducing human subjectivity and improving IVF success rates.[10][11][12]
AIVF's EMA platform improved IVF success rates, reducing failed pregnancies and increasing accuracy in embryo selection. The company reports that EMA provides a 38% higher accuracy level compared to evaluations by embryologists alone, with embryos scoring high on EMA demonstrating a 70% probability of successful pregnancy.[13][14][15] The use of EMA has been shown to reduce the number of IVF cycles needed to achieve a fetal heartbeat by over 27.5%.[16][17]
In 2024, AIVF unveiled the first AI-based embryo evaluation for euploidy screening test based on time-lapse videos. This instant non-invasive AI tool successfully refines the genetic quality assessment of embryos in IVF clinics.[18]
AIVF's EMA platform is commercially available across Europe, Australia, Brazil, South Korea and North America. In 2023, the company announced its preparations to launch its platform in the United States.[19]
References
[edit]- ^ Ghert-Zand, Renee (2022-05-16). "Women entrepreneurs are leading the charge to make Israel a femtech powerhouse". Time of Israel. Retrieved 2024-08-06.
- ^ "About Israel Innovation Authority". English Innovation Site. Retrieved 2024-08-06.
- ^ "AIVF revolutionizes in vitro fertilization". www.altaroc.pe. Retrieved 2024-08-06.
- ^ Press, Gil. "Will This AI Launch The Next Stage Of In-Vitro Fertilization (IVF)?". Forbes. Retrieved 2024-08-06.
- ^ "Israeli IVF treatment developer earns CE approval for AI-based solution". The Jerusalem Post | JPost.com. 2021-04-29. Retrieved 2024-08-06.
- ^ Spiro, James (2021-04-28). "AiVF receives European CE Mark for its AI-based IVF treatments". CTECH - www.calcalistech.com. Retrieved 2024-08-06.
- ^ "AiVF Raises $25M in Series A Funding for Its AI-based IVF Platform". Retrieved 2024-08-06.
- ^ AIVF (2022-06-26). "AiVF raises $25 Million to transform fertility with the first operational AI-based IVF platform". StartupHub.ai. Retrieved 2024-08-06.
- ^ Gilboa, Daniella; Koren, Gideon; Barer, Yael; Katz, Rachel; Rotem, Ram; Lunenfeld, Eitan; Shalev, Varda (December 2019). "Assisted reproductive technology and the risk of pediatric cancer: A population based study and a systematic review and meta analysis". Cancer Epidemiology. 63: 101613. doi:10.1016/j.canep.2019.101613. ISSN 1877-783X. PMID 31606679.
- ^ Trate, Becca (2024-03-08). "5 Q's for Daniella Gilboa, co-founder and CEO of AIVF". Center for Data Innovation. Retrieved 2024-08-06.
- ^ "Fertility startup AIVF buys lab management software company ART Compass". MobiHealthNews. 2022-10-25. Retrieved 2024-08-06.
- ^ "Israeli startup AiVF: Non-invasive AI can ID genetic characteristics in embryos". www.israelhayom.com. Retrieved 2024-08-06.
- ^ Miller, Sara (2024-06-09). "Israeli AI Platform Delivering Baby Boom For IVF Pregnancies". NoCamels. Retrieved 2024-08-06.
- ^ Kragh, Mikkel Fly; Karstoft, Henrik (July 2021). "Embryo selection with artificial intelligence: how to evaluate and compare methods?". Journal of Assisted Reproduction and Genetics. 38 (7): 1675–1689. doi:10.1007/s10815-021-02254-6. ISSN 1058-0468. PMC 8324599. PMID 34173914.
- ^ "AIVF expands launching the first AI-Powered IVF solution at the Perfetto Clinic in Goiânia, Brazil". Intelligent CIO LATAM. Retrieved 2024-08-06.
- ^ Lundin, K; Bentzen, J G; Bozdag, G; Ebner, T; Harper, J; Le Clef, N; Moffett, A; Norcross, S; Polyzos, N P; Rautakallio-Hokkanen, S; Sfontouris, I; Sermon, K; Vermeulen, N; Pinborg, A (2023-09-25). "Good practice recommendations on add-ons in reproductive medicine". Human Reproduction. 38 (11): 2062–2104. doi:10.1093/humrep/dead184. ISSN 0268-1161.
- ^ Rubin, Sarah C.; Abdulkadir, Mawerdi; Lewis, Joshua; Harutyunyan, Aleksandr; Hirani, Rahim; Grimes, Cara L. (2023-04-27). "Review of Endometrial Receptivity Array: A Personalized Approach to Embryo Transfer and Its Clinical Applications". Journal of Personalized Medicine. 13 (5): 749. doi:10.3390/jpm13050749. ISSN 2075-4426. PMC 10219399. PMID 37240919.
- ^ "Searchable". www.eshre.eu. Retrieved 2024-08-06.
- ^ Press, Gil. "Will This AI Launch The Next Stage Of In-Vitro Fertilization (IVF)?". Forbes. Retrieved 2024-08-06.